This non-invasive, targeted technology uses ultrasonic energy to stimulate or inhibit deeper brain structures without incisions or radiation.
We have numerous ongoing
clinical trials involving condition-specific protocols. Treatment time and target location vary depending on clinical indication.
Anti-Inflammatory, Insulin-Sensitizing NE3107
This open-label, phase II study explores the relationship between insulin functioning and cognitive health among older adults suffering from early stages of dementia.
This study will involve a three-month intervention using an oral drug designed to enhance insulin sensitivity and reduce systemic inflammation. Outcomes will be evaluated according to changes in cognitive performance measures, advanced neuroimaging, spinal fluid, and serological markers.
Mild cognitive impairment, mild dementia
The pursuit of an effective therapeutic intervention for patients suffering from Alzheimer's and Parkinson's conditions has inspired interest in tyrosine kinase inhibitors (TKIs) such as bosutinib.
Our ongoing expanded phase I clinical trial studies the use of bosutinib for the investigational treatment of degenerative dementias.
Click here to see our report presented to Pfizer demonstrating unexpected early results that show a marked improvement in functional scores among participants with Parkinson’s and Alzheimer’s diseases.
This open-label study evaluates the safety and feasibility of plasmapheresis as an intervention for patients with age-related frailty.
Plasmapheresis is the filtering of blood to remove toxic elements.
In our plasmapheresis protocol, a percentage of the plasma in the patient's blood is removed and replaced with albumin.
Near-infrared laser stimulation has garnered interest for a variety of cited benefits, some of which include cognitive enhancement, mood regulation, cellular recovery and mitochondrial repair.
Our study investigates the use of transcranial near-infrared laser stimulation as a potential therapeutic modality for a variety of neurological conditions, including those listed above. Treatment duration and target areas depend on the clinical indication.
This clinical trial investigated the use of ProdromeNeuro, an Omega–3 nutritional supplement oil, among participants with aging-related cognitive decline.
Results from this preliminary study indicated that ProdromeNeuro consumption was correlated with improved DHA plasmalogen levels as well as optimized memory function among older adults.
For more information on ProdromeNeuro check out our press release here.
**Phase II to be announced in 2022**